Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12613000717752
Ethics application status
Approved
Date submitted
28/06/2013
Date registered
1/07/2013
Date last updated
23/07/2018
Type of registration
Prospectively registered
Titles & IDs
Public title
The effect of resveratrol supplementation on gut hormone secretion, gastric emptying, and blood glucose responses to meals in patients with type 2 diabetes
Query!
Scientific title
A randomised placebo controlled crossover trial to evaluate the effects of 5 weeks resveratrol supplementation on GLP-1 secretion, gastric emptying, and postprandial glycaemia in patients with type 2 diabetes mellitus
Query!
Secondary ID [1]
282754
0
Nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
type 2 diabetes mellitus
289489
0
Query!
Condition category
Condition code
Metabolic and Endocrine
289816
289816
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Each patient will undergo two 5 week treatment periods, one with resveratrol 500mg capsules twice daily and one with placebo, in double- blind, randomised fashion, separated by 5 weeks. They will attend the laboratory on the first and last day of each treatment period to consume a mashed potato meal labelled with 13C-octanoic acid. Compliance will be monitored by capsule counts at each study visit and by twice weekly telephone calls.
Query!
Intervention code [1]
287420
0
Treatment: Drugs
Query!
Comparator / control treatment
Matching placebo capsules
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
289887
0
Plasma total GLP-1 concentrations
Query!
Assessment method [1]
289887
0
Query!
Timepoint [1]
289887
0
Concentrations measured at T = -5, 15, 30, 45, 60, 90, 120, 150, 180 and 240 min in relation to consumption of the test meal at T = 10 min
Query!
Secondary outcome [1]
303482
0
Gastric half-emptying time as measured by 13C-octanoic breath test
Query!
Assessment method [1]
303482
0
Query!
Timepoint [1]
303482
0
Breath samples collected at T=5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 min and then every 15 min until T = 240 min
Query!
Secondary outcome [2]
303483
0
Blood glucose concentrations
Query!
Assessment method [2]
303483
0
Query!
Timepoint [2]
303483
0
Concentrations measured at T = -5, 15, 30, 45, 60, 90, 120, 150, 180 and 240 min in relation to consumption of the test meal at T = 10 min
Query!
Eligibility
Key inclusion criteria
- Patients with a diagnosis of type 2 diabetes by WHO criteria (plasma glucose 7 mmol/L or greater fasting, or 11.1 mmol/L or greater two hours after a glucose challenge) or with a history of HbA1c 6.5% or greater, managed by diet alone.
- Body mass index (BMI) 20 - 35 kg/m2
- Age 20 – 75 years
- Males and post-menopausal females (the latter based on history).
- HbA1c 7.9% or less
- Haemoglobin above the lower limit of the normal range (ie. >130g/L in males and 120g/L in females) and ferritin above the lower limit of normal (ie. >15 mcg/L in females and 30 mcg/L in males)
Query!
Minimum age
20
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Use of any medication, within a period of 5 half-lives or less before the study, that may influence gastrointestinal motor function (eg: opiates, anticholinergics, levodopa, calcium-channel antagonists, beta blockers, clonidine, nitrates, tricyclic antidepressants, selective serotonin re-uptake inhibitors, phosphodiesterase type 5 inhibitors, sumatriptan, metoclopramide, domperidone, cisapride, tegaserod, or erythromycin).
- Intake of > 20 g alcohol on a daily basis, or cigarette smoking
- Inability to tolerate the standardized meals (eg. strict vegetarians, subjects with food allergies such as egg allergy, and those on a gluten-free diet).
- History of gastrointestinal disease, including chronic abdominal symptoms or a diagnosis of gastroparesis
- Unstable cardiac disease, specifically those with cardiac symptoms such as angina or dyspnea, not adequately controlled by medications.
- Impaired renal function (eGFR of <60 mL/min/1.73 m2).
- Impaired liver function (liver enzymes twice the upper limit of normal or greater).
- Donation of blood within the previous 3 months
- Participation in any other research studies within the previous 3 months
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
numbered containers
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
computer-generated random number table
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Crossover
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
15/07/2013
Query!
Actual
30/09/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
22/08/2014
Query!
Date of last data collection
Anticipated
Query!
Actual
14/01/2015
Query!
Sample size
Target
15
Query!
Accrual to date
Query!
Final
14
Query!
Recruitment in Australia
Recruitment state(s)
SA
Query!
Funding & Sponsors
Funding source category [1]
287523
0
Hospital
Query!
Name [1]
287523
0
Gum Bequest, Endocrine and Metabolic Unit, Royal Adelaide Hospital
Query!
Address [1]
287523
0
Endocrine and Metabolic Unit, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia 5000
Query!
Country [1]
287523
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
Royal Adelaide Hospital
Query!
Address
North Terrace Adelaide South Australia 5000
Query!
Country
Australia
Query!
Secondary sponsor category [1]
286268
0
None
Query!
Name [1]
286268
0
Query!
Address [1]
286268
0
Query!
Country [1]
286268
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
289501
0
Royal Adelaide Hospital Human Research Ethics Committee
Query!
Ethics committee address [1]
289501
0
Level 3, Hanson Institute Royal Adelaide Hospital, North Terrace, Adelaide SA 5000
Query!
Ethics committee country [1]
289501
0
Australia
Query!
Date submitted for ethics approval [1]
289501
0
Query!
Approval date [1]
289501
0
30/05/2013
Query!
Ethics approval number [1]
289501
0
130229
Query!
Summary
Brief summary
Resveratrol, which is a nutritional supplement derived from certain plant foods including red grapes, has the potential to improve blood sugar levels in patients with type 2 diabetes by uncertain mechanisms. In this study, we aim to identify the effects of resveratrol on the rate of gastric emptying, blood sugar levels and blood levels of hormones produced by the intestines
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
41102
0
A/Prof Chris Rayner
Query!
Address
41102
0
Discipline of Medicine Royal Adelaide Hospital North Terrace Adelaide SA 5000
Query!
Country
41102
0
Australia
Query!
Phone
41102
0
+61 8 82222916
Query!
Fax
41102
0
+61 8 82233870
Query!
Email
41102
0
[email protected]
Query!
Contact person for public queries
Name
41103
0
A/Prof Chris Rayner
Query!
Address
41103
0
Discipline of Medicine Royal Adelaide Hospital North Terrace Adelaide SA 5000
Query!
Country
41103
0
Australia
Query!
Phone
41103
0
+61 8 82222916
Query!
Fax
41103
0
+61 8 82233870
Query!
Email
41103
0
[email protected]
Query!
Contact person for scientific queries
Name
41104
0
A/Prof Chris Rayner
Query!
Address
41104
0
Discipline of Medicine Royal Adelaide Hospital North Terrace Adelaide SA 5000
Query!
Country
41104
0
Australia
Query!
Phone
41104
0
+61 8 82222916
Query!
Fax
41104
0
+61 8 82233870
Query!
Email
41104
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
Source
Title
Year of Publication
DOI
Embase
Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: A randomized controlled trial.
2016
https://dx.doi.org/10.3945/ajcn.115.117440
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF